Figure 5.

CRISPR CAS9-mediated knockdown of Lbp improves systemic glucose metabolism. (A) Body weight gain, (B) ratio between fat mass and lean mass, (C) representative hematoxylin staining of epididymal adipose tissue (scale bars = 100 μm), (D) frequency of adipocyte sizes, (E) fasting glucose levels, (F) fasting insulin levels, and (G–H) glucose tolerance in the mice treated with CRISPR CAS9-Lbp or adenovirus negative control. n = 14. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001 determined by Student's t-test.